LivingGLP1
Study S002129

Impact of Exenatide on Sleep Duration and Quality in Type 2 Diabetes

ClinicalTrials.gov record

Registration

Registration
NCT01416649
Study type
OBSERVATIONAL
Status
COMPLETED
Enrollment
8
Start
2011-02-01
Primary completion
2021-04-21
Lead sponsor
University of Chicago
Conditions
Type 2 Diabetes
Interventions
DRUG:Exenatide
Results posted
FALSE

Registered primary outcomes

  • Sleep duration and sleep efficiency [at the end of 3 months of treatment with the medication]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.